STOCKHOLM, September 3rd, 2025, Moberg Pharma AB (OMX: MOB) today announces that shareholders representing more than 10 percent of the Company's shares have proposed to expand the Board of Directors by two additional members. This proposal suggests increased shareholder representation and further focus on international sales at the Board level.
In addition, the proposal includes the intention to withdraw the authorization previously granted to issue new shares. This reflects Moberg Pharma's solid financial position, as the Company is well-capitalized and does not foresee a need to utilize the authorization.
The current Board members have endorsed this proposal, which aims to further broaden the Board's expertise and governance capacity in line with Moberg Pharma's growth strategy. The proposal will be addressed at an Extraordinary General Meeting. A formal notice of the EGM will be provided in a subsequent press release.
For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se
About this information
The information was released for public distribution on September 3rd, 2025, at 8:00 am CEST.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).